<DOC>
	<DOCNO>NCT00685204</DOCNO>
	<brief_summary>Milataxel new taxane may several advantage currently available taxanes . The current study design determine response rate oral Milataxel patient malignant Mesothelioma . The study specifically target patient recur progressive disease follow previous chemotherapy .</brief_summary>
	<brief_title>An Efficacy Study Milataxel ( TL139 ) Administered Orally Malignant Mesothelioma</brief_title>
	<detailed_description>This non-randomized , multicenter , open label , single agent phase II study . Patients malignant mesothelioma recur progressed follow chemotherapy , qualify study , receive milataxel 60 mg/m2 orally Day 1 21 day cycle . If toxicity great Grade 1 severity occur , patient receive 75 mg/m2 second subsequent cycle . Patients receive drug total six cycle . Milataxel administration excess six cycle permit discretion Investigator patient stable respond disease .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Patients must histologically cytologically confirm malignant mesothelioma receive pemetrexed combination cisplatin part chemotherapeutic regimen . Prior cancer therapy pemetrexed/cisplatin must complete least 30 day prior first cycle milataxel ; prior radiotherapy ( le 25 % bone marrow ) must complete least 30 day prior study enrollment . Patients must measurable disease Modified RECIST criterion Patients must life expectancy least 12 week ECOG performance status 0 , 1 2 Patients must 18 year age . Patients must adequate organ system function . Patients must able comply protocol treatment procedure . Patients know brain metastasis may include study , provide clinically stable . Recovered acute toxicity cause prior cancer therapy , except alopecia . Patients must receive chemotherapeutic treatment malignant mesothelioma pemetrexed platinum agent cisplatin . Patients grade 2 great peripheral neuropathy . Prior cancer therapy complete within 30 day prior first cycle milataxel ; radiotherapy complete less 30 day prior study enrollment ; patient recover radiationrelated toxicity ; patient receive concurrent anticancer therapy , include trastuzumab , bevacizumab investigational agent onstudy ; patient great 2 prior radiotherapy treatment . Patients know sensitivity alcohol . Patients significant intercurrent illness . Patients symptomatic CNS metastasis . Patients major surgery within past 14 day . Patients require likely require strong modifier CYP450 activity take prior milataxel administration Patients receive high dose steroid ( dexamethasoneequivalent dose 4 mg per day ) . Patients malabsorption syndrome , disease significantly affect gastrointestinal function , major resection stomach small bowel could affect absorption study drug . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>